Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge-fund level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialAn announcement from Astria Therapeutics ( (ATXS) ) is now available. On October 14, 2025, Astria Therapeutics entered into a merger agreement with BioCryst Pharmaceuticals and a BioCryst subsidiary under which the subsidiary will merge into Astria, leaving Astria as a wholly owned unit of BioCryst, and BioCryst has filed the related registration statement while Astria has issued a definitive proxy statement for a stockholder vote on the deal. In mid-December 2025, two stockholder lawsuits were filed in New York state court alleging that Astria and its board negligently issued a false and misleading registration statement regarding the merger and seeking injunctive relief, damages, and fees, but the company has rejected the claims as without merit, arguing that any alleged misstatements are not material or actionable and pledging to vigorously defend the litigation while continuing to move the merger process forward. The most recent analyst rating on (ATXS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page. Spark’s Take on ATXS Stock According to Spark, TipRanks’ AI Analyst, ATXS is a Neutral. Astria Therapeutics’ stock score reflects its status as a development-stage biotech company. The strong balance sheet provides financial stability, but the lack of revenue and increasing losses pose significant risks. Mixed technical indicators and valuation challenges further contribute to a cautious outlook. To see Spark’s full report on ATXS stock, click here. More about Astria Therapeutics Astria Therapeutics, Inc. is a Delaware-based biopharmaceutical company, with its shares held by public stockholders and overseen by a board of directors, that is the target of an acquisition by BioCryst Pharmaceuticals, under which it would become a wholly owned subsidiary following completion of a planned merger. Average Trading Volume: 2,078,799 Technical Sentiment Signal: Hold Current Market Cap: $732.4M For a thorough assessment of ATXS stock, go to TipRanks’ Stock Analysis page.